Redeye provides an update in relation to Enzymatica’s Q4 2023 report. The report came in a bit under our expectations. Moreover, the company carries out a rights issue of SEK27.4m, which aligns with our estimate. Based on the report, we make some changes in our forecasts; however, the changes do not render an updated fair value range, including a base case of SEK6.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Enzymatica Q4 - Important year ahead and an expected rights issue

© Modular Finance, source Nordic Press Releases